BTIG analyst Mark Massaro raised the price target on Guardant Health (NASDAQ: GH) to $195.00 (from $190.00) while maintaining a Buy rating.

The analyst comments "As we previewed, Guardant drove another strong beat and raise in Q2, and we were impressed with its strong +63% Y/Y core oncology volume growth, and record +22k growth q/q in its nascent Shield screening business. While in very early days, GH drove +313% Y/Y Shield volume growth and +257% Y/Y Shield revenue growth, both nicely ahead of our expectations. Q2 was marked by Guardant hitting on an extraordinary number of catalyst, including ACS guideline inclusion for Shield, FDA approval of Guardant360 Liquid CDx, and to everyone's surprise, Guardant obtained commercial payor coverage on its Shield test from large health plan UnitedHealth (UNH, Not Rated). We view Guardant as a "must own" market leader in specialty diagnostics, and we continue to believe GH's attractive oncology, screening, and MRD opportunities remain in early innings of adoption. Guardant remains our Top Pick, and we reiterate our Buy rating, and raise our PT from $190 to $195."